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ABSTRACT 
Objective High body mass index (BMI) is an established risk factor of 
gastroesophageal reflux symptoms (GERS). The aim of this study was to clarify if 
weight loss reduces GERS. 
Design The study was part of the Nord-Trøndelag health study (the HUNT study), a 
prospective population-based cohort study conducted in Nord-Trøndelag County, 
Norway. All residents of the county from 20 years of age were invited. In 1995-7 
(HUNT 2) and 2006-9 (HUNT 3), 58,869 and 44,997 persons, respectively, 
responded to a questionnaire on heartburn and acid regurgitation. Among these, 
29,610 persons (61% response rate) participated at both times and were included in 
the present study. The association between weight loss and reduction of GERS was 
calculated using logistic regression. The analyses were stratified by antireflux 
medication and the results adjusted for sex, age, cigarette smoking, alcohol 
consumption, education, and physical exercise. 
Results Weight loss was dose-dependently associated with a reduction of GERS 
and an increased treatment success with antireflux medication. Among persons with 
>3.5 units decrease in BMI, the adjusted OR of loss of any (minor or severe) GERS 
was 1.98 (95% CI 1.45 to 2.72) when using no or less than weekly antireflux 
medication, and 3.95 (95% CI 2.03 to 7.65) when using at least weekly antireflux 
medication. The corresponding ORs of loss of severe GERS was 0.90 (95% CI 0.32 
to 2.55) and 3.11 (95% CI 1.13 to 8.58). 
Conclusion Weight loss was dose-dependently associated with both a reduction of 
GERS and an increased treatment success with antireflux medication in the general 
population. 
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STUDY HIGHLIGHTS 
WHAT IS CURRENT KNOWLEDGE 
 The prevalence of gastroesophageal reflux symptoms (GERS) is high and 
increasing in Western populations 
 High body mass index is a risk factor of GERS 
 The effect of weight loss on GERS is not clear 
WHAT IS NEW HERE 
 Weight loss was associated with a reduction of GERS in the general 
population 
 There was a dose-response relationship between weight loss and reduction of 
GERS 
 Weight loss was associated with an increased treatment success with 
antireflux medication




Gastroesophageal reflux disease (GERD) is a highly prevalent disease in Western 
populations,(1, 2) associated with a decreased health-related quality of life(3, 4) and 
an increased risk of esophageal adenocarcinoma.(5, 6) The Montreal definition and 
classification of GERD states that: “GERD is a condition which develops when the 
reflux of stomach contents causes troublesome symptoms and/or complications” and 
the definition recognizes that heartburn and acid regurgitation are characteristic 
symptoms of GERD.(7, 8) Overweight, defined according to the World Health 
Organization’s classification as body mass index (BMI) ≥25 kg/m2,(9) increases the 
risk of gastroesophageal reflux symptoms (GERS)(10-12) and is independently 
associated with esophageal adenocarcinoma.(11) The increasing weight seen in the 
general population will have unfortunate effects on the prevalence of GERD.(13-15) 
Weight loss may be of great importance in the prevention and treatment of the many 
individuals suffering from GERD. The aim of this study was to clarify if weight loss 
reduces GERS in a large population-based cohort followed prospectively over time. 
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METHODS 
Study population and design 
The study was performed as part of a large population-based study, the Nord-
Trøndelag health study (the HUNT study). The HUNT study is an on-going 
prospective cohort study based on repeated health surveys of the entire adult 
population of Nord-Trøndelag County, Norway. All residents in the county from 20 
years of age have been invited to participate in three surveys, entitled HUNT 1 (1984-
6), HUNT 2 (1995-7), and HUNT 3 (2006-8). The HUNT study includes data on a 
wide range of health related items gathered from written questionnaires answered by 
the participants, clinical examinations performed by trained personnel, and blood 
samples taken from the participants.(16) GERS were assessed in HUNT 2 and 
HUNT 3, and these two surveys constituted the base of the present study. In 
addition, GERS were assessed in a ‘non-responder study’ (Mini-Q) after HUNT 3 in 
2009, where those who did not participate in HUNT 3 were invited.(2, 16) The 
individuals who participated in HUNT 2 and were followed up in Mini-Q were also 
eligible for inclusion in the present study (figure 1). 
 
Assessment of gastroesophageal reflux symptoms 
GERS were assessed by a questionnaire in HUNT 2 (1995-7) and HUNT 3/Mini-Q 
(2006-9). The participants replied to the question: ‘To what degree have you had 
heartburn or acid regurgitation during the previous 12 months?’ with one of three 
response alternatives: ‘no complaints’, ‘minor complaints’, or ‘severe complaints’. In a 
validation study after HUNT 2, 25% of those reporting minor complaints and 95% of 
those reporting severe complaints had at least weekly symptoms.(10) In Mini-Q, 
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where frequency of complaints also was assessed, the corresponding proportions 
were 31% and 98%.(2) We defined ‘any GERS’ to include all participants reporting 
minor or severe complaints and ‘severe GERS’ to include only those reporting severe 
complaints.  
 
Assessment of body mass index 
BMI equals weight in kilograms divided by the square height in meters (kg/m2). 
Weight and height were objectively measured under standardized conditions and by 
trained personnel at screening stations in both HUNT 2 and HUNT 3. In Mini-Q, 
weight and height measurements were self-reported.  
 
Assessment of co-variables 
Co-variables in the analyses were chosen using accepted criteria for a confounding 
factor, i.e. being associated with the outcome (GERS), associated with the exposure 
(weight loss), and not an effect of the exposure or outcome under study.(17) The 
variables selected as potential confounders were sex, age, cigarette smoking, alcohol 
consumption, education, and physical exercise. These co-variables were assessed 
through questionnaires in HUNT 3/Mini-Q, except for education which was assessed 
in HUNT 2. The participants reported cigarette smoking status, frequency of alcohol 
drinking during the previous 12 months, length of education, and average frequency 
of physical exercise. 
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Assessment of antireflux medication 
Data on antireflux medication, i.e. proton pump inhibitors (PPIs), histamine-2-receptor 
antagonists (H2RAs), or antacids, was gathered from HUNT 3 and from the 
Norwegian Prescription Database (NorPD). Until 2010, PPIs and H2RAs (except 
small packages of low dose H2RAs) have only been available in Norway through a 
prescription from a physician, and only small packages of low dose H2RAs and 
antacids have been available over the counter (OTC). In HUNT 3, frequency of OTC 
antireflux medication use was assessed through written questionnaires. Since 2004, 
data on all prescribed medication in Norway has been collected in the NorPD. By 
linkage of the HUNT study and the NorPD, data on all prescribed antireflux 
medication among the study participants was gathered. Using number of 
prescriptions and number of tablets in each prescription, average frequency of 
antireflux medication was estimated during the HUNT 3 study period. Thus, all 
antireflux medication should be accounted for in HUNT 3: OTC use through the 
HUNT 3 questionnaires and prescribed use through the NorPD. Only those who 
actually were prescribed an antireflux medication were included in the data from the 
NorPD and therefore it was not possible to distinguish between never users and 
participants with missing information on medication use. All participants with missing 
data on antireflux medication were therefore regarded as never users. 
 
Statistical methods 
Logistic regression was used to analyze the association between weight loss and 
reduction of GERS, providing odds ratios (ORs) with 95% confidence intervals (CIs). 
The participants who had any GERS at baseline (HUNT 2) and no GERS at follow-up 
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(HUNT 3/Mini-Q), defined as ‘loss of any GERS’, were compared with those who had 
any GERS at both time points, i.e. ‘stable any GERS’. The participants who had 
severe GERS at baseline and no or minor GERS at follow-up, defined as ‘reduction 
of severe GERS’, were compared with those who had severe GERS at both time 
points, i.e. ‘stable severe GERS’. Finally, those who had severe GERS at baseline 
and no GERS at follow-up, defined as ‘loss of severe GERS’, were compared with 
those who had severe GERS at both time points, i.e. ‘stable severe GERS’. The 
absolute change in BMI units between the two time points was calculated and five 
categories reflecting this change were used in the analyses: <0.5 units change 
(reference category), 0.5-1.5 units decrease, >1.5-3.5 units decrease, >3.5 units 
decrease, and ≥0.5 units increase. In the statistical model adjustments were made by 
categorization of age (<40, 40-49, 50-59, 60-69, or ≥70 years), cigarette smoking 
status (never smoker, previous smoker, or current smoker), frequency of alcohol 
consumption (less than weekly or at least weekly), years of education (≤12 years or 
>12 years), and frequency of physical exercise (less than weekly or at least weekly). 
Antireflux medication was not considered a confounder according to the definition 
above. Instead, the analyses were stratified into two groups of antireflux medication 
use at follow-up: no or less than weekly or at least weekly. The analyses were 
performed with the statistics and data analysis software Stata, version 11.2, by 
StataCorp LP, Texas, US. 
 
Study approval 
The study was approved by the Regional Committee for Medical and Health 
Research Ethics, Central-Norway (ID 4.2009.328). All participants in the HUNT study 
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signed a written consent form before participating, which stated the purpose of the 
study and the possibility of future research and linkage to other registries. 




In HUNT 2 (1995-7) and HUNT 3/Mini-Q (2006-9), 58,869 individuals (64% response 
rate) and 44,997 individuals (49% response rate) reported their complaints with 
GERS, respectively. Among these, 29,610 individuals participated in both surveys 
and were included in the present study. This corresponds to a response rate of 61% 
at follow-up, after excluding the 10,535 participants in HUNT 2 who were no longer 
resident in the county at the time of HUNT 3/Mini-Q or had deceased before HUNT 
3/Mini-Q (non-eligible for follow-up) (figure 1). 
Characteristics 
At baseline (HUNT 2), 9299 individuals (31.4%) reported any GERS (any GERS 
cohort) and 1553 individuals (5.2%) reported severe GERS (severe GERS cohort). 
Of the any GERS cohort, 2398 individuals (25.8%) reported no GERS at follow-up in 
HUNT 3/Mini-Q, i.e. ‘loss of any GERS’ (table 1). Of the severe GERS cohort, 284 
individuals (18.3%) reported no GERS at follow-up in HUNT 3/Mini-Q, i.e. ‘loss of 
severe GERS’ (table 1), 729 individuals (46.9%) reported minor GERS, and 1013 
(65.2%) reported no or minor GERS, i.e. ‘reduction of severe GERS’ (table 1).  
 
The mean BMI among all the participants increased between the two time points. The 
participants with loss or reduction of GERS had a lower increase in BMI than those 
with stable GERS (table 1). Those with loss or reduction of GERS were younger, had 
higher education, and used less antireflux medication than those with stable GERS 
for both cohorts (table 1). There was no difference in the proportion of current 
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cigarette smokers among the subgroups (table 1). In the any GERS cohort, the 
proportion of women was higher among those with loss of GERS compared to those 
with stable GERS (table 1). In the severe GERS cohort, alcohol consumption was 
more frequent among those with loss or reduction of GERS compared to those with 
stable GERS, and physical exercise was more frequent among those with loss or 
reduction of GERS (table 1).
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Table 1 Characteristics of cohort reporting gastroesophageal reflux symptoms (GERS)* in HUNT 2 & HUNT 3/Mini-Q (N=29,610) 
  Stable  Loss of  Stable  Reduction of  Loss of 
 any GERS  any GERS†  severe GERS  severe GERS†  severe GERS† 
Number (%) 6901 (74.2)  2398 (25.8)  540 (34.8)  1013 (65.2)  284 (18.3) 
BMI‡ (kg/m
2
), HUNT 2          
 Mean (sd) 27.3 (4.0)  27.2 (4.3)  27.7 (4.2)  28.1 (4.3)  27.9 (4.3) 
 Missing, no. (%) 23 (0.3)  21 (0.9)  2 (0.4)  5 (0.5)  2 (0.7) 
BMI (kg/m
2
) change§          
 Mean (sd) 1.3 (2.4)  0.5 (2.7)  1.3 (2.4)  0.9 (2.7)  0.6 (2.8) 
 Missing, no. (%) 78 (1.1)  46 (1.9)  7 (1.3)  19 (1.9)  7 (2.5) 
Sex          
 Women, no. (%) 3415 (49)  1271 (53)  277 (51)  521 (51)  143 (50) 
Age (years), HUNT 3/Mini-Q          
 Mean (sd) 59.8 (12.6)  57.4 (14.1)  60.8 (12.7)  60.2 (13.6)  58.7 (14.5) 
Cigarette smoking, HUNT 3/Mini-Q          
 Never, no. (%) 2428 (35.2)  921 (38.4)  188 (34.8)  304 (30.0)  79 (27.8) 
 Previous, no. (%) 2332 (33.8)  737 (30.7)  182 (33.7)  383 (37.8)  120 (42.3) 
 Current, no. (%) 1822 (26.4)  631 (26.3)  141 (26.1)  279 (27.5)  73 (25.7) 
 Missing, no. (%) 319 (4.6)  109 (4.5)  29 (5.4)  47 (4.6)  12 (4.2) 
Alcohol consumption, HUNT 3/Mini-Q         
 <weekly, no. (%) 4292 (62.2)  1498 (62.5)  363 (67.2)  649 (64.1)  173 (60.9) 
 ≥weekly, no. (%) 2377 (34.4)  816 (34.0)  153 (28.3)  327 (32.3)  103 (36.3) 
 Missing, no. (%) 232 (3.4)  84 (3.5)  24 (4.4)  37 (3.7)  8 (2.8) 
Education, HUNT 2          
 ≤12 years, no. (%) 5602 (81.2)  1837 (76.6)  469 (86.9)  842 (83.1)  233 (82.0) 
 >12 years, no. (%) 1162 (16.8)  511 (21.3)  56 (10.4)  146 (14.4)  41 (14.4) 
 Missing, no. (%) 137 (2.0)  50 (2.1)  15 (2.8)  25 (2.5)  10 (3.5) 
Physical exercise, HUNT 3/Mini-Q          
 <weekly, no. (%) 1672 (24.2)  576 (24.0)  156 (28.9)  272 (26.9)  71 (25.0) 
 ≥weekly, no. (%) 5047 (73.1)  1754 (73.1)  363 (67.2)  721 (71.2)  210 (73.9) 
 Missing, no. (%) 182 (2.6)  68 (2.8)  21 (3.9)  20 (2.0)  3 (1.1) 
Antireflux medication||, HUNT 3         
 Never or <weekly, no. (%)¶ 3742 (54.2)  2112 (88.1)  87 (16.1)  505 (49.9)  195 (68.7)       
 ≥weekly, no. (%) 3159 (45.8)  286 (11.9)  453 (83.9)  508 (50.1)  89 (31.3)       
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* GERS: self-reported degree of complaints with heartburn or acid regurgitation during the previous 12 months.       
† Loss of any GERS: any GERS at baseline, no GERS at follow-up; Reduction of severe GERS: severe GERS at baseline, no or 
minor GERS at follow-up; Loss of severe GERS: severe GERS at baseline, no GERS at follow-up. The severe GERS group is a 
subset of the any GERS group. 
      
‡ BMI: body mass index.       
§ BMI change: BMI HUNT 3/Mini-Q - BMI HUNT 2.       
|| Antireflux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids.       
¶ Participants with no information on antireflux medication were included in never or <weekly category.       
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Association between weight loss and gastroesophageal reflux symptoms 
In the crude analyses, without considering antireflux medication or any potential 
confounder, weight loss was dose-dependently associated with loss or reduction of 
GERS (p-value for trend ≤0.012) (table 2). When stratified by antireflux medication, 
weight loss was associated with an increased treatment success with antireflux 
medication when used at least weekly (table 2). Among participants with no or less 
than weekly antireflux medication, there was a 2-fold increase in the adjusted odds of 
loss of any GERS among participants with >3.5 units decrease in BMI compared to 
participants with <0.5 units change in BMI (OR 1.98, 95% CI 1.45 to 2.72) (table 2). 
Among participants with at least weekly antireflux medication, the corresponding 
odds increased 4-fold (OR 3.95, 95% CI 2.03 to 7.65) (table 2). The association 
between weight loss and any GERS was dose-dependent regardless of antireflux 
medication (p-value for trend <0.001) (table 2). In the severe GERS cohort, there was 
no association between weight loss and GERS among participants with no or less 
than weekly antireflux medication. The adjusted ORs of reduction and loss of severe 
GERS among those with >3.5 units decrease in BMI compared to those with <0.5 
units change in BMI was 0.58 (95% CI 0.16 to 2.10) (table 2) and 0.90 (95% CI 0.32 
to 2.55) (table 2), respectively, and there was no dose-response association (p-value 
for trend 0.804 and 0.189, respectively) (table 2). However, among those with at least 
weekly antireflux medication, the corresponding ORs was 2.12 (95% CI 0.89 to 5.02) 
(table 2, figure 2) and 3.11 (95% CI 1.13 to 8.58) (table 2, figure 3), respectively, and 
there was a dose-response association (p-value for trend 0.008 and 0.047, 
respectively) (table 2). Since the crude and adjusted ORs were similar when stratified 
by antireflux medication, only the adjusted data are presented in table 2. 
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Table 2 Odds ratio (OR) with 95% confidence interval (95% CI) for loss or reduction of gastroesophageal reflux symptoms (GERS)*  
compared with stable GERS by change in body mass index (BMI)† and antireflux medication‡ 
        
   
Loss of any GERS§ 
 
Reduction of severe GERS§ 
 
Loss of severe GERS§ 
Crude 
             
 




No. OR 95% CI 
 
No. OR 95% CI 
 




5542 0.72 0.63 to 0.82 
 
897 0.83 0.63 to 1.10 
 




1589 1.00 Reference 
 
278 1.00 Reference 
 




970 1.22 1.03 to 1.46 
 
157 0.88 0.59 to 1.33 
 




770 1.38 1.15 to 1.66 
 
137 1.87 1.16 to 3.02 
 




304 2.42 1.88 to 3.11 
 
58 1.32 0.70 to 2.47 
 
58 1.51 0.79 to 2.88 
 
p-value for trend|| 
  
<0.001   
  
0.001   
  










              No or less than weekly antireflux medication 
        
 




No. OR¶ 95% CI 
 
No. OR¶ 95% CI 
 




3100 0.67 0.57 to 0.78 
 
304 0.74 0.36 to 1.51 
 
304 0.72 0.43 to 1.19 




939 1.00 Reference 
 
95 1.00 Reference 
 
95 1.00 Reference 




616 1.14 0.92 to 1.40 
 
65 0.50 0.20 to 1.22 
 
65 0.83 0.41 to 1.67 




485 1.25 0.99 to 1.56 
 
54 1.64 0.49 to 5.48 
 
54 1.13 0.56 to 2.31 




198 1.98 1.45 to 2.72 
 
22 0.58 0.16 to 2.10 
 
22 0.90 0.32 to 2.55 
     
 
p-value for trend|| 
  
<0.001   
  
0.804   
  
0.189   










     
              
     
At least weekly antireflux medication 
         
     
 




No. OR¶ 95% CI 
 
No. OR¶ 95% CI 
 




2022 0.99 0.67 to 1.45 
 
518 1.04 0.71 to 1.51 
 
518 0.81 0.42 to 1.56 




507 1.00 Reference 
 
145 1.00 Reference 
 
145 1.00 Reference 




267 1.29 0.75 to 2.19 
 
78 1.16 0.66 to 2.03 
 
78 0.94 0.36 to 2.48 




213 1.79 1.05 to 3.05 
 
67 2.24 1.19 to 4.21 
 
67 0.91 0.32 to 2.55 




66 3.95 2.03 to 7.65 
 
30 2.12 0.89 to 5.02 
 
30 3.11 1.13 to 8.58 
     
 
p-value for trend|| 
  
<0.001   
  
0.008   
  
0.047   
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* GERS: self-reported degree of complaints with heartburn or acid regurgitation during the previous 12 months. 
     
† Change in BMI: BMI HUNT 3/Mini-Q - BMI HUNT 2. 
     
‡ Antireflux medication: proton pump inhibitors, histamin-2-receptor antagonists, and antacids. 
     
§ Loss of any GERS: any GERS at baseline, no GERS at follow-up; Reduction of severe GERS: severe GERS at baseline, no or minor GERS at 
follow-up; Loss of severe GERS: severe GERS at baseline, no GERS at follow-up. The severe GERS group is a subset of the any GERS group.      
|| p-value for trend: Wald test for linear trend. 
     
¶ Adjusted for sex, age, cigarette smoking, alcohol consumption, education, and physical exercise 
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DISCUSSION 
In this study, weight loss was dose-dependently associated with a reduction of 
GERS, especially among those with the highest decrease in BMI. Weight loss was 
also associated with an increased treatment success with antireflux medication. 
 
The major strengths of this study are 1) the population-based design, reducing 
selection bias; 2) the large sample size, reducing the risk of chance findings and 
making subgroup analyses possible; 3) the prospective design, minimizing recall 
bias; 4) the large selection of variables assessed in the HUNT study, making 
adjustments for potential confounders possible; and 5) the linkage with the NorPD, 
complementing the data on antireflux medication. The limitations are 1) the loss to 
follow-up between the two time points, making selection bias possible; 2) the 12 
months recall period used in the questionnaire, making recall bias possible; 3) the 
long time period between the assessments of GERS, making short term fluctuations 
in GERS impossible to evaluate; 4) residual confounding, which cannot be excluded 
in observational research, although the choice of co-variables was restrictive to avoid 
spurious effects; and 5) self-reported height and weight in Mini-Q, reducing the 
measurement accuracy of BMI.  
 
Nord-Trøndelag County is representative of the Norwegian population at large, 
making the findings generalizable.(18) Selection bias due to loss of follow-up is 
probably small since there were only minor differences in the distribution of the study 
variables among all the HUNT 2 participants (N=58,869) compared with the cohort 
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which was followed-up (N=29,610): there was no difference in the mean BMI (26 
kg/m2) or mean alcohol consumption (2.5 times/month); the proportion of women was 
52% and 54%; the mean age was 48.5 years and 45.8 years; the proportion of never 
smokers was 47% and 48% and of daily smokers 30% and 27%; the proportion with 
>12 years of education was 21% and 24%; and the proportion who did no exercise 
weekly was 9% and 6%, respectively. The 12 months recall period used in the 
questionnaire is a sub-optimal long period to recall GERS. However, this should not 
be a major threat to the validity of the study, since most people with GERS, at least of 
a more severe type, are likely to be able to report their symptoms. The passage of 11 
to 12 years between the surveys does not capture the short-term fluctuations in 
symptoms in individual subject. Moreover, some people with GERS might have 
developed Barrett´s esophagus between the surveys, which might reduce symptoms 
although the reflux disease remains. However, this should be limited to only a few 
people in the study. In Mini-Q, height and weight were self-reported, reducing 
measurement accuracy of BMI in this subpopulation. However, the number of 
individuals from Mini-Q was limited to n=938 (10.1%) and n=190 (12.2%) in the any 
GERS cohort and the severe GERS cohort, respectively. Assuming that self-reported 
weight is an underestimate of the actual weight, this would overestimate any weight 
loss from baseline in the study, and dilute the effect of weight loss on loss or 
reduction of GERS, make the presented ORs closer to the null. In English, 
“heartburn” and “regurgitation” are known to be words that the general public not 
understands adequately. However, in Norwegian this is much less a problem. The 
Norwegian words “brystbrann”/”halsbrann” and “sure oppstøt” used in this study are 
frequently used in the common language and are understood by the general public in 
the same way as health care professionals and researchers do. 
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Previous research on the effect of weight loss on GERS is limited, conflicting, and 
suffers from varying definitions of GERD. Two randomized, double-blind, sham 
controlled trials of gastric balloon distension on 42 and 28 extremely obese patients 
with pH-verified reflux, but without grade C or D oesophagitis (Los Angeles 
classification(19)) or large (>3 cm) hiatus hernia on endoscopy, found that weight 
loss was followed by reduced reflux.(20, 21) An uncontrolled prospective study of 34 
patients (mean BMI 23.5) with troublesome GERS, and either normal endoscopy or 
grade I oesophagitis (Savary-Miller classification(22)), found improvement in reflux 
symptom score after 6 weeks with a decrease of mean BMI of 1.7.(23) Another 
uncontrolled prospective study of 18 volunteers (mean BMI 43.5) with GERS, found 
improvement in symptom score after a mean of 4 days with an average weight loss of 
1.7 kg.(24) In the Nurses’ Health Study from the United States there was a 36% 
reduction in the risk of at least weekly GERS among women with at least 3.5 
decrease in BMI compared with those with no change in BMI (OR 0.64, 95% CI 0.42 
to 0.97).(25) However, a randomized trial of 20 obese patients (mean BMI 31.4 at 
inclusion) with pH-verified reflux, erosive oesophagitis, and daily GERS, did not find 
any effect on GERS with a mean decrease in BMI of 2.6 to 4.8 units.(26) This study 
included participants with hiatus hernia, which contributes to the occurrence of GERD 
and is irreversible with weight loss. The only previous population-based study of the 
effect of weight change on GERS was from the United States and followed 637 
individuals over a median of 10.5 years (mean age 62 years and 53% females at 
follow-up) and found no relation between weight change and change in reported 
GERD symptoms.(27) A major limitation of that study was, however, the use of self-
reported height and weight.  
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Our results favor the hypothesis that weight loss improves GERS. Due to the 
observational design of the study, strict causality cannot be implied. However, the 
consistent and dose related association between weight loss and reduction of GERS, 
which is preserved after adjustment for possible important confounders, argues for a 
valid conclusion. The data also indicates that even greater benefits might be seen in 
overweight individuals who achieve a larger weight loss. According to the Montreal 
definition and classification, “GERD is a condition which develops when the reflux of 
stomach contents causes troublesome symptoms and/or complications” and it further 
states that “In population-based studies, mild symptoms occurring 2 or more days a 
week, or moderate/severe symptoms occurring more than 1 day a week, are often 
considered troublesome by patients”.(8) As the validation studies of our questionnaire 
showed that 95-98% of the participants who reported severe GERS had at least 
weekly complaints, those reporting severe GERS in our study can be regarded as 
having GERD according to the Montreal definition. It seems that the weight loss 
needs to be substantial to improve severe GERS. This is probably due to the strong 
association between BMI and GERS. Even BMI in the upper normal range has been 
shown to be associated with GERS compared with BMI in the lower normal 
range.(25) In addition, weight loss without regular use of antireflux medication does 
not seem to be sufficient. This probably reflects an advanced stage of disease in 
these subjects, i.e. esophagitis or symptoms related to the presence of hiatal hernia, 
which does not resolve only with weight loss. However, weight loss was associated 
with an increased chance of treatment success with antireflux medication. 
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CONCLUSION 
In this large prospective population-based cohort study weight loss was dose-
dependently associated with reduction of GERS and increased chance of treatment 
success with antireflux medication. The study also suggests that patients with GERD 
using regular antireflux medication might benefit from weight reduction. 
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FIGURE LEGENDS 
Figure 1 Flowchart of participants. Number of individuals (N) at each stage and the 
response rate (%). The response rate was calculated from those eligible for follow-
up, excluding those who were no longer resident in the county or had deceased (non-
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